Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluating the Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in New-Onset Gastric Cancer and Related Gastric Conditions Among Type 2 Diabetes Patients: A Population-Based Cohort Analysis

  • By

  • Oscar Hou In Chou

  • Vinod Kumar Chauhan

  • Cheuk To Skylar Chung

  • Lei Lu

  • Teddy Tai Loy Lee

  • Zita Man Wai Ng

  • Karin Kai Wing Wang

  • Sharen Lee

  • Haipeng Liu

  • Ronald Ting Kai Pang

  • Apichat Kaewdech

  • Bernard Man Yung Cheung

  • Gary Tse

  • Jiandong Zhou

  • August 31, 2026

Share

  • 1

    The article is an erratum for a study on sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients.

  • 2

    The erratum corrects inaccurate affiliation details from the original publication.

  • 3

    The original article was published in Gastric Cancer, volume 27, pages 947–970.

  • 4

    The DOI for the original article is https://doi.org/10.1007/s10120-024-01512-7.

  • 5

    The correction notice indicates that the original article has been amended accordingly.

Original Source(s)

Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study

  • by Oscar Hou In Chou, Vinod Kumar Chauhan, Cheuk To Skylar Chung, Lei Lu, Teddy Tai Loy Lee, Zita Man Wai Ng, Karin Kai Wing Wang, Sharen Lee, Haipeng Liu, Ronald Ting Kai Pang, Apichat Kaewdech, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou

  • August 31, 2026

Related Content

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min
Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.